Article Text

other Versions

PDF
The problem of non-superiority: what do we know after KOMET?
  1. Andreas C Sönnichsen1,2
  1. 1Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria
  2. 2Institute of General Practice and Family Medicine, University of Witten/Herdecke, Witten, Germany
  1. Correspondence to Andreas C Sönnichsen, Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria; andreas.soennichsen{at}pmu.ac.at

Statistics from Altmetric.com

Levetiracetam is a well established second generation antiepileptic drug. It can be used as adjunctive or monotherapy treatment of partial-onset seizures with or without secondary generalisation, or of generalised tonic-clonic seizures.1 The efficacy of Levetiracetam has been demonstrated in numerous randomised controlled explanatory trials in comparison to placebo, but we know little about its effectiveness compared to standard therapy. So far only one randomised controlled head-to-head-trial compared levetiracetam and carbamazepine, and did not find a significant difference regarding seizure freedom rate after 6 months or 1 year.2 The ‘Keppra versus Older Monotherapy in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles